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Abstract Human extracellular ribonucleases (RNase), together 
with other members of the mammalian RNase superfamily, can 
be classified into four different enzyme types on the basis of their 
structural, catalytic and/or biological properties. Their occur-
rence and main distinctive features have been described, and 
catalytic differences (action on single- and double-stranded 
RNAs, dependence of enzyme activity on pH, ionic strength 
and cations, and hydrolysis of cyclic nucleotides) have been 
comparatively analyzed and discussed. In addition, some data 
considered here concerning human nonpancreatic-type RNases 
may support the suggestion [Chuchillo et al. (1993) FEBS Lett. 
333, 207-210] that the enzyme 'ribonuclease', presently classified 
as 'hydrolase', should be reclassified as 'transferase'. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The ribonucleases (RNase) of mammals and other verte-
brates constitute a large superfamily of enzymes having 
greatly diverse functions other than a simple digestive role. 
Protein sequences from many species are known and their 
molecular evolution has been studied [1]. These enzymes are 
widely distributed in various organs and body fluids and, 
apart from pancreatic RNases, the physiological roles of non-
digestive extracellular ribonucleases found in tissues other 
than pancreas are poorly understood. However, recent inves-
tigations have suggested that many members of this super-
family have important biological actions (reviewed in [1-3]) 
including neurotoxicity, angiogenic activity, immunosuppres-
sivity, and antitumor activity. Some nondigestive extracellular 
RNases also serve as cytotoxic agents in host defence in high-
er plants and mammals [3] and their potential use as thera-
peutic agents for human disorders has recently been suggested 
[4,5]. 
In this review we will summarize the information available 
on the main structural and catalytic properties of the major 
human RNases (in comparison with other animal ribonu-
cleases), and focus on the amino acid residues likely to be 
involved in determining some of their catalytic differences. 
*Corresponding author. Fax: (39) 81-552-12-17 
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2. Classification, occurrence and features of human RNases 
Human ribonucleases have been grouped (together with 
other mammalian RNases) into two broad classes [6] usually 
designated as 'secretory' and 'nonsecretory' RNases. How-
ever, it is now clear that these designations are not appropri-
ate and might be confusing. Indeed, in some human 'nonse-
cretory' tissues (for example, brain [7] and kidney [8]) the 
only, or the major, expressed ribonuclease has been charac-
terized as a 'secretory' RNase. In addition, it has been shown 
[9] that the human genomic DNA coding for eosinophil-de-
rived neurotoxin (EDN), the so-called human 'nonsecretory' 
RNase [10-12], encodes a signal sequence typical of secreted 
proteins. Hence, for all mammalian extracellular RNases we 
prefer to use here the term 'pancreatic-type' (pt) instead of 
'secretory' to classify the members of the RNase family (not 
only found in pancreas [13] but also in other human tissues 
and body fluids [14]) characterized by showing sequences as 
well as structural and catalytic properties similar to those of 
bovine [15] or human [13,16,17] pancreatic RNases. We also 
adopt here the term (previously suggested by us [17]) 'non-
pancreatic-type' (npt) instead of 'nonsecretory' to categorize 
the members of the RNase family (expressed in tissues other 
than pancreas and also found in several fluids [14]) character-
ized by having sequence and catalytic properties similar to 
those of bovine kidney RNase K2 [18] or human EDN/liver 
RNase [11,12,17]. Other members of the RNase superfamily 
(for example, porcine liver RNase PL3 [19,20], and human 
plasma RNase 4 [21,22]) constitute a third distinct RNase 
family and could be referred to as 'pt/npt' RNases. These 
enzymes (characterized by having a blocked N-terminus, a 
unique two-residue deletion and other sequence features [19-
22]) are indeed structurally more similar to ptRNases [16,19-
22], but share some catalytic properties with both (pt) and 
(npt) ribonucleases [12,13,17,19-22]. 
Many human RNases have been isolated and characterized 
by several laboratories, and in different organs several var-
iants of the same gene product have been shown to exist. 
However, at present, only five distinct proteins with RNase 
activity have been identified. Recently, the existence of a sixth 
human RNase has been reported [23]. So far, this novel hu-
man ribonuclease, named RNase K6, has been identified only 
in the genomic DNA, and a single mRNA transcript (1.5 kb) 
was detected in many human tissues. However, the deduced 
amino acid sequence of this RNase is 47% and 72% identical 
to the sequences of human nptRNase [9-12] and bovine kid-
ney RNase K2 [18], respectively [23]. Thus, according to the 
genetic nomenclature recently introduced [9,22] and on the 
basis of the designations proposed above, the five structurally 
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defined human ribonucleases shown in Fig. 1 can be classified 
as follows. 
2.1. ptRNase 1 
This enzyme [16] has been isolated mostly from pancreas 
[13], but enzymes which are products of the same gene (with 
different post-translational modifications) have also been pu-
rified from urine [24], seminal plasma [25], brain [7], and kid-
ney [8]. In this enzyme, depending on the tissue origin, the 
glycosylation patterns of the three Asn-Xaa-Thr/Ser sites 
(Asn-34, Asn-76, Asn-88) are, indeed, quite different 
[16,26,27]. The primary structure of this enzyme (Fig. 1) 
shows 70% identity with that of bovine RNase A, most of 
the amino acid substitutions being conservative [16,26]. 
2.2. nptRNase 2 
This enzyme [10,11] (also named EDN) occurs predomi-
nantly in spleen [28], eosinophils [29], liver [30], and placenta 
[31], but has been also isolated from urine [24], and kidney 
[8]; all these proteins (with quite similar glycosylation patterns 
[32]) are products of the same gene. In the sequence of this 
RNase, five amino acid positions (17, 59, 65, 84 and 92) with 
asparagine-linked carbohydrates have been identified [10] and 
their iV-glycan structure [32] is very different from that re-
ported for ptRNase 1 [27]. In addition, a novel post-transla-
tional modification (an a-mannopyranosyl residue C-glyco-
sydically attached to the 2-position of the indole ring of 
Trp-7) has been recently demonstrated [33]. The primary 
structure of nptRNase 2 (Fig. 1) is only 35% identical to 
that of ptRNase 1. The major differences (RNase A number-
ing system) are: (i) a six-residue deletion (positions 17-22); (ii) 
the insertion of two, two and nine residues in three external 
loops of the molecule; (iii) the addition of three residues at the 
amino terminus. In particular, several amino acids that are 
considered important in mammalian ptRNases, like Lys-7, 
Arg-10 (P2 subsite), Lys-66 (Po subsite), and Phe-120 are 
replaced in a nonconservative way [10]. It is worth noticing 
that both the enzymes isolated from eosinophils [29] and liver 
[30] have been shown to possess a potent neurotoxicity linked 
to their RNase activity [12]. 
2.3. nptRNase 3 
This protein [9,34], also named eosinophil cationic protein 
(ECP), isolated thus far only from granulocytes [29], is very 
basic (pi, 10.8) and highly homologous (70% identity) to 
nptRNase 2 [34]. In the sequence of this RNase (Fig. 1) there 
are three N-linked glycosylation sites [34] with complex oligo-
saccharides similar to those found in nptRNase 2 [29]. This 
protein is less neurotoxic than nptRNase 2 but is a more 
potent helmintotoxin also having antibacterial activity as 
well as showing cytotoxicity for mammalian cells in vitro 
[34]. While its neurotoxicity seems to be linked to the ribonu-
cleolytic activity [12], RNase activity is not essential for cyto-
toxicity [35]. Its ribonucleolytic activity is much lower than 
that of nptRNase 2, but otherwise catalytic properties are 
similar [36]. 
2.4. ptlnptRNase 4 
This enzyme [22] was first isolated from tumor-cell-condi-
tioned medium [21] and later from normal human plasma 
[22]; recently the messenger RNA coding for this RNase 
was detected by Northern analysis in a number of human 
somatic tissues, including pancreas, liver, lung, skeletal 
muscle, heart, kidney and placenta, but not brain [37]. No 
N-linked glycosylation sites have been observed in the se-
quence of this protein, the only post-translational modifica-
tion being the pyroglutamic acid found at its amino terminus 
[22]. Its sequence (Fig. 1) is more similar to that of human 
ptRNase 1 (43% identity) than to those of nptRNase 2 and 
RNase 3 (31% and 30% identity, respectively), but shows a 
unique deletion of two residues (positions 77 and 78 of RNase 
1) [22]. In addition, this human RNase was shown to be 
highly homologous (about 90% identity) to porcine and bo-
vine liver RNases [22]. 
2.5. angRNase 5 
This protein [38] (called angiogenin), originally isolated 
from tumor-cell-conditioned medium [38] on the basis of its 
potent in vivo angiogenic activity, was also purified from nor-
mal human plasma [39]. Its principal biological role is to in-
duce the formation of new blood vessels. Despite its remark-
able structural similarity (Fig. 1) to pt/nptRNase 4, ptRNase 
1, and nptRNase 2 (39%, 35%>, and 27% sequence identity, 
respectively [10,11,22,38]), angRNase 5 shows an unusual ri-
bonucleolytic activity [40,41], which differs markedly both in 
magnitude and specificity from RNase activity of the other 
human RNases. The extremely weak ribonucleolytic activity 
(toward standard RNase substrates [40]) of angRNase 5 
which is, however, essential for angiogenicity, seems to be in 
part due to the obstruction of the pyrimidine binding site (as 
observed in the homologous RNase A structure) by Gln-117 
[42]. 
3. Catalytic differences between human ribonucleases 
The five structurally defined human RNases described 
above, despite their remarkable sequence similarities (Fig. 1) 
are catalytically quite different and, excluding angRNase 5 
because of its unusual ribonucleolytic activity, the remaining 
four RNases show catalytic properties which are characteristic 
of one or both the two major RNase types, ptRNase 1 and 
nptRNase 2. 
1 10 20 30 40 
RNase A KETAAAKFERQHMDSSTSAASSSNYCNQMMKSRNLTKDRCKPV 
RNase 1 — K E S R A K K F Q R Q H M D S D S S P S S S S T Y C N Q M M R R R N M T Q G R C K P V 
RNase 2 KPPQFTWAQWFETQHINMTSQQ C T N A M Q V I N N Y Q R R C K N Q 
RNase 3 R P P Q F T R A Q W F A I Q H I S L N P P R C T I A M R A I N N Y R W R C K N Q 
RNase 4 — Q D G M Y Q R F L R Q H V H P E E T G G - S D R Y C N L M M Q R R K M T L Y H C K R F 
RNase 5 - - Q D N S R Y T H F L T Q H Y D A K P Q G R - D D R Y C E S I M R R R G L T S P - C K D I 
50 60 70 80 90 
RNase A NTFVHESLADVQAVCSQKNVACKNGQT--NCYQSYSTMSITDCRETGSS 
RNase 1 NTFVHEPLVDVQNVCFQEKVTCKNGQG--NCYKSNSSMHITDCRLTNGS 
RNase 2 N T F L L T T F A N W H V C G N P N M T C P S N K T R K N C H H S G S Q V P L I H C N L T T P S 
RNase 3 N T F L R T T F A N W N V C G N Q S I R C P H N R T L N N C H R S R F R V P L L H C D L I N P G 
RNase 4 NTFIHEDIWNIRSICSTTNIQCKNGKM--NCHEGV--VKVTDCRDTGSS 
RNase 5 N T F I H G N K R S I K A I C E N K N G N P H R E N L R I S K S S F Q V T T C K L H G G S 
100 110 120 
RNase A K--YPNCAYKTTQANKHIIVACEGN PYVPVHFDASV 
RNase 1 R--YPNCAYRTSPKERHIIVACEGS PYVP VHFDASVEDST 
RNase 2 PQNISNCRYAQTPANMFYIVACDNRDQRRDPPQYPWPVHLDRII 
RNase 3 A Q N I S N C R Y A D R P G R R F Y W A C D N R D - P R D S P R Y P W P V H L D T T I 
RNase 4 R--APNCRYRAIASTRRWIACEGN PQVPVHFDG 
RNase 5 P--WPPCQYRATAGFRNVWACENG L PVHLDQSIFRRP 
Fig. 1. Alignment of the amino acid sequences of the five structur-
ally defined human RNases with that of bovine pancreatic RNase 
A. Residues conserved in all six RNases are indicated (boldface 
type). The references for the sequences are given in the text. 
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Fig. 2. Action of human ptRNase 1 and bovine pancreatic RNase 
A towards poly(A) and double-stranded polyribonucleotides. Figure 
prepared with data published in [17]. 
3.1. Activity on double-stranded RNA and poly (A) 
The first notable difference between these two RNase types 
is that ptRNase 1 (Fig. 2) is active on poly(A) and double-
stranded (ds) RNA (two orders of magnitude more than 
RNase A) while nptRNases 2 and 3 are totally inactive on 
those substrates [17,36]. Recently, it has been suggested that in 
bovine RNase A [43] (and very probably in all mammalian 
ptRNases) Asp-83 could play an important role in the activity 
towards poly(A). Interestingly, nptRNases at the correspond-
ing position lack Asp-83. The enzymatic cleavage of dsRNA 
by ptRNases may occur, according to a mechanism already 
proposed by us [17,44], as the consequence of the preferential 
binding of the RNase molecule to short single-stranded se-
quences of the substrate transiently exposed by spontaneous 
thermal fluctuations. This model is supported by the observa-
tion that ptRNase 1 shows a remarkable DNA-helix-destabi-
lizing action, while nptRNase 2 as well as nptRNase 3 have 
no such activity [17,36,44]. A complementary model, based on 
the binding of the enzyme to single nucleotides wound off the 
double-helix, was also advanced [45]. The DNA-unwinding 
activity of bovine RNase A has been related to the multiplic-
ity of phosphate-binding subsites of the enzyme protein [46]. 
In this respect, the higher degrading activity shown by human 
ptRNase 1 towards dsRNA (Fig. 2) could be explained by a 
stronger local positive electrostatic potential developing on 
the enzyme because of the presence of three basic amino 
acid residues (Arg-4, Lys-6, Arg-32) at positions where in 
bovine RNase A three neutral residues are present instead 
[15,16]. In contrast, nptRNases 2 and 3, although higly basic 
proteins, do not show the extended multisite cationic region 
(nine basic residues) which characterizes mammalian 
ptRNases [46], i.e. many of their positive charges are located 
far from the enzyme active site. 
In conclusion, while human nptRNases 2 and 3 (and pos-
sibly also other mammalian nptRNases) may be defined as 
true single-strand specific RNases, mammalian ptRNases 
might by now be classified as single-strand preferring RNases. 
3.2. Substrate preference 
As summarized in Fig. 3, in contrast to bovine RNase A 
and ptRNase 1 which degrade poly(C) faster than RNA and 
poly(U), human nptRNases 2 and 3 but also pt/nptRNase 4 
strongly prefer poly(U) over poly(C). This preference seems to 
be due to a significant reduction of their affinity for poly(C), 
rather than to an increased preference for poly(U) 
[17,21,22,36] and could be attributed to the different micro-
environment of the Bl subsite of both nptRNases and pt/ 
nptRNase 4. In these enzymes, in fact, Thr-45 is conserved 
but Ser-123 is not, and this might prevent productive binding 
of the cytosine moiety of the substrate molecule. However, 
Ser-123 is replaced by other residues (Thr, Tyr) in several 
mammalian ptRNases [1]. Recently, it has been suggested 
[47] that in nptRNase 2 the side-chain of Gln-40, like Ser-
123 of RNase A, can either accept or donate hydrogen bonds 
and could be responsible for binding the 0-4 of uracil or N-4 
of cytosine. In addition, in human pt/nptRNase 4 (and also in 
porcine 'pt/npt' RNase PL3 [20]) the phenylalanine residue at 
position 42 (Val-43 in ptRNase 1) has been suggested to play 
an important role through its possible interaction with uracil 
[22]. 
3.3. Influence of ionic strength and cations 
The activity of the two major human RNase types towards 
yeast RNA has been shown to be differently influenced by 
ionic strength and divalent cations [17]. The increasing of 
the NaCl concentration from 50 to 300 mM enhances the 
activity of ptRNase 1, while the activity of nptRNase 2 de-
creases above 150 mM. This could be due to the stronger 
positive electrostatic potential of ptRNase 1 developing in 
the interaction of the enzyme protein with the polyanionic 
substrate. Another difference between the two RNase types 
is that while the activity of nptRNase 2 is not influenced by 
low zinc ion concentrations (0.5 mM), that of ptRNase 1 is 
strongly inhibited. Magnesium ions, instead, have no effect on 
the activity of both RNase types [17]. This could be partly 
ascribed to a stoichiometric bond possibly forming in 
ptRNase 1 between a zinc ion and His-12 and His-119, but 
not in nptRNase 2 [17] because of structural differences of its 
catalytic site [47]. 
Table 1 
Structural and catalytic characteristics of human RNases compared with those of other members of RNase superfamily 
Enzyme 
Bovine RNase A 
ptRNase 1 
pt/nptRNase 4 
Bovine RNase K2 
nptRNase 2 
Turtle RNase 
Onconase 
Position 66 
Lys 
Lys 
Lys 
Lys 
Pro 
Ser 
deletion 
Phe-120 
+ 
+ 
+ 
— 
-
— 
+ 
Asp-121 
+ 
+ 
+ 
+ 
+ 
+ 
-
Position 122 
Ala 
Ala 
Ala 
Lys 
Arg 
Lys 
Gly 
pH optimum on 
yeast RNA 
8.0 
8.0 
7.5 
6.5 
6.5-7.0 
? 
6.0 
Activity on cyclic 
nucleotides 
+ 
+ 
+ 
? 
-
— 
+ 
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■ Yeast RNA 
B Poiy(U) 
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0 Viral ssRNA 
Fig. 3. Substrate preference of human ribonucleases compared with 
that of bovine pancreatic RNase A. Figure prepared with data pub-
lished in [17,21,36]. The data concerning pt/nptRNase 4 (obtained 
by Shapiro et al. [21]) were transformed into the enzyme units de-
fined in [17,36] and included in the figure only to allow a rough 
comparison. 
3.4. Influence of pH on RNase activity and hydrolysis of 
2',3'-cyclic nucleotides 
Two other remarkable catalytic differences of the two major 
human RNase types are their pH optima with RNA as sub-
strate, and the so-called 'second step' of the RNase-catalyzed 
reaction [17]. Human ptRNase 1 shows indeed optimal activ-
ity with RNA as substrate at pH 8.0, and a hydrolytic activity 
towards 2',3'-cyclic nucleotides which is comparable to that of 
bovine RNase A [7,8,13,17,24]. Human nptRNase 2, shows its 
pH optimum shifted to lower pH values (6.5-7.0) with yeast 
RNA as substrate [17,24,28], and is unable to catalyze the 
hydrolysis of cyclic nucleotides at a measurable rate 
[12,17,20]; this is also true for nptRNase 3 [36]. To under-
stand these points, particularly important are the amino acid 
residues (RNase A numbering system) specified in Table 1. 
In all mammalian ptRNases Lys-66 has an important role 
[46,48], and it has been suggested that a basic amino acid at 
either position 66 or 122 may be of primary importance for a 
'normal' ribonucleolytic activity [48]. It is quite interesting 
that human nptRNase 2 and turtle pancreas RNase [1,48] 
lack Lys-66 (see Table 1) but have a basic residue at position 
122, while angiogenin, nptRNase 3, and also onconase (an 
RNase from Rana pipiens oocytes) [49], lacking a basic residue 
at both those positions, show indeed a very low RNase activ-
ity [36,30,48,49]. 
The importance of Asp-121 in bovine RNase A has been 
demonstrated also by site-directed mutagenesis [50]. We think 
that, in all mammalian ptRNases, the possible interaction 
between Asp-121 and His-119 [51] could also serve to stabilize 
at pH 8.0 the protonated form of His-119, which is essential 
for catalytic activity. In human nptRNase 2 (Fig. 1), as well as 
in bovine kidney RNase K2 [18,52] and turtle RNase [1,48], 
while Asp-121 is a conserved residue, a basic amino acid is 
present (Table 1) at position 122 (where in ptRNases a neutral 
residue is found), which plays a crucial phosphate-binding 
role [48]. Now, a basic residue at position 122 may indeed 
influence the possible interaction between Asp-121 and His-
119 and therefore be responsible for a lower pH value (6.5-
7.0) necessary to maintain His-119 in its protonated form. In 
agreement with this idea, human nptRNase 2 and bovine 
RNase K2 (Table 1) show in fact such a lower pH optimum. 
Moreover, according to our hypothesis, turtle RNase 
although being a pancreatic enzyme should have a pH opti-
mum similar to that of nptRNases. Unfortunately, for this 
enzyme no experimental data concerning this point are avail-
able thus far. 
In conclusion, in all members of the vertebrate extracellular 
RNase superfamily a pH optimum of about 8.0 toward RNA 
seems to be ascribable to the presence of an aspartate residue 
at position 121. Its absence (as it occurs in onconase, Table 1) 
or the presence in some ribonucleases of a basic residue at 
position 122 could be responsible for the lower pH optimum 
of these enzymes. 
As discussed above, human nptRNases 2 and 3 differ from 
human ptRNase 1 and pt/nptRNase 4 as well as from other 
mammalian ptRNases for many structural and catalytic prop-
erties. One of the most important difference consists in the 
fact that although nptRNases efficiently catalyze the depoly-
merization of RNA, they do not show any detectable (cata-
lytically significant) hydrolytic activity towards 2',3'-cyclic 
phosphodiesters [12,17,36], which are usually considered inter-
mediates in the RNase A-catalyzed cleavage of RNA. Regard-
ing this point, work from different laboratories [46,53,54] 
demonstrated that bovine RNase A and other pancreatic-
type RNases release into solution cyclic phosphodiesters as 
true products of the transphosphorylation of RNA, which 
can be hydrolysed in a separate slower reaction. It is worth 
noticing here that (Table 1) while the ribonucleases capable of 
hydrolysing cyclic nucleotides have a phenylalanine at posi-
tion 120, those lacking this residue are inactive on the same 
substrates. Accordingly, it has been observed [55] that while a 
substitution of leucine for phenylalanine at position 120 low-
ers the activity of bovine RNase A on cyclic nucleotides about 
100-fold, the replacement of leucine by phenylalanine in hu-
man angRNase 5 (at a site equivalent to position 120 in 
RNase A) increases the activity of angRNase 5 against cyclic 
nucleotides up to 100-fold [56]. These observations seem to 
indicate that the absence in a RNase of the aromatic side-
chain of Phe-120 while being responsible for the inability of 
the enzyme to catalyze efficiently the hydrolysis of cyclic phos-
phodiesters, does not influence RNA transphosphorylation. 
On the basis of these data, human nptRNases might repre-
sent a proper indication that the enzyme ribonuclease does not 
require a water molecule as a substrate for RNA cleavage. 
This may support the suggestion already advanced [53,54] 
that ribonuclease (presently classified as hydrolase) has indeed 
evolved primarily to catalyze RNA transphosphorylation. If 
so, it should be reclassified as transferase. 
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